Back to discover
Disease

Infections

Late-stage therapeutic developmentActively researchedRising momentum
29
Publications
23
Clinical trials
7
Related conditions
2024
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

The immunology of sickness metabolism.

Research2024-08-06Cellular & molecular immunology

Inflammation unites diverse acute and chronic diseases.

Research2024-07-24European journal of clinical investigation

The global role of G6PD in infection and immunity.

Research2024-06-13Frontiers in immunology

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

Research2024-02-01The New England journal of medicine

Approval: Xerava (EMA)

Regulatory2018-09-20EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Major developments
Important regulatory approvalHigh impact
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.2026-04-27
Clinical Milestones6View
Industry & Market3View
Regulatory Updates1View
  • 2026-04-27Approval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Mavorixaforapproved

Approval — Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syn… (2026)

Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)

Tecovirimatapproved

Approval — Tecovirimat SIGA is indicated for the treatment of the following viral infections in adul… (2022)

Approval — Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM)… (2020)

Tigecyclineapproved

Approval — Tygecycline Accord is indicated in adults and in children from the age of eight years for… (2020)

Delafloxacinapproved

Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)

Posaconazoleapproved

Approval — Posaconazole Accord is indicated for use in the treatment of the following fungal infecti… (2019)

Clinical trials

13 sponsors · 3 new · 0 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
23
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApprovalMavorixafor· Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. source ↗
2022emaApprovalErtapenem sodium· Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1): Intra-abdominal infections Community acquired pneumonia Acute gynaecological infections Diabetic foot infections of the skin and soft tissue (see section 4.4) Prevention Ertapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2022emaApprovalTecovirimat· Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13kg: Smallpox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13kg . Tecovirimat SIGA should be used in accordance with official recommendations. source ↗
2020emaApprovalAmikacin sulfate· Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. source ↗
2020emaApprovalTigecycline· Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4) Complicated intra-abdominal infections (cIAI) Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2019emaApprovalDelafloxacin· Quofenix is indicated for the treatment of the following infections in adults: acute bacterial skin and skin structure infections (ABSSSI), community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2019emaApprovalPosaconazole· Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. source ↗
2019emaApprovalPosaconazole· Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

29 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19992024
Major themes8
  • Infections5
  • Immunity, Innate2
  • Inflammation2
  • Adaptation, Physiological1
  • Adaptive Immunity1
  • Anorexia1
  • Antigens, CD191
  • Cardiovascular Diseases1
Leading journals6
  • Frontiers in immunology3
  • Nature3
  • Annual review of immunology2
  • Cellular & molecular immunology2
  • Annals of internal medicine1
  • Biotechnology journal1
Leading researchers8
  • Aggarwal BB1
  • Aigner M1
  • Albert ML1
  • Anand P1
  • Andersson U1
  • Angulo C1
  • Anzueto A1
  • Ardura MI1
Affiliations (unnormalised)6
  • 2nd Department of Medicine and Cardiology Centre1
  • Aarhus University Hospital1
  • Acibadem City Clinic Tokuda Hospital1
  • Africa Centres for Disease Control and Prevention1
  • Aix Marseille Université1
  • and the Institute of Clinical Microbiology1

Related conditions

7 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Infections are conditions caused by invasion of the host by microorganisms, their toxins, or parasites that can produce pathological disease. The literature grounding frames infections broadly across microbiology, parasitology, virology, immunology, diagnosis, therapy, metabolism, and complications.

Causes

Infections are caused by invasion with microorganisms, their toxins, or parasites. The supplied grounding also links infections with pathogen-derived molecules that stimulate innate immune responses.

Pathophysiology

The grounding emphasizes host innate immune activation as a central mechanism in infection. CRP is described as an acute inflammatory protein that rises at sites of infection and participates in complement, apoptosis, phagocytosis, nitric oxide release, and production of inflammatory mediators, while HMGB1 is presented as a mediator of innate immune signaling through TLR4 that drives cytokine release and tissue damage. The microbiome and mucus barrier are also highlighted as part of host defense at mucosal surfaces.

Risk factors

The supplied grounding does not support a specific list of risk factors for infections. It does note associations with smoking, diet, genetic factors, epigenesis, homeostasis, and host-microbiome interactions, but not as established risk factors for infection in general.

Current standard of care

The grounding supports treatment at a broad modality level only. It indicates that infections are generally managed with therapy directed at the infectious process, and that research includes immune-targeted approaches such as strategies aimed at HMGB1/TLR4 and the use of CRP as a marker of infection, but it does not provide a specific standard treatment class for all infections.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.